CENTENE CORP

Centene Corp. climbs to #19 in Forbes’ biggest U.S. firms, driving managed‑care growth and tech‑driven care to meet rising Medicare, Medicaid demands and cost‑pressure challenges.

Centene Corp’s new share‑transfer filing and voluntary employee buy‑out program demonstrate a sharp focus on cost‑control, tech‑driven care, and shareholder value amid a shifting managed‑care market.

Centene Corp’s new CFO signals a strategic shift toward value‑based care, technology partnership and tighter financial discipline—boosting EBITDA and free cash flow while navigating Medicaid‑driven growth and regulatory risk.

Glenmark Pharmaceuticals’ 2025/26 results show modest revenue growth, rising EPS, and a ₹2.50/share dividend, amid raw‑material price volatility and regulatory pressures.

Centene’s latest earnings boost shares 9% and highlights a steady, long‑term growth trend, showing why investors view the healthcare firm as a resilient, value‑creating asset.

Centene’s latest moves: New York member outreach, transparent executive holdings, and Health Net’s award‑winning service—boosting care, governance, and patient satisfaction.

Centene Corp’s May 2026 AGM agenda reveals new board hires, auditor appointment, a 10% placement facility renewal and performance‑rights awards, highlighting a strategic focus on value‑based care, flexible capital, and shareholder‑aligned governance.

Centene’s $225,000 grant for a St. Louis medical respite program shows how the health‑tech company turns philanthropy into cost‑saving, payer‑friendly strategy—reducing ED visits, cutting Medicaid spending, and strengthening its social‑impact brand.

Centene Corp’s rising value: analyst praise, institutional buying and CMS policy gains highlight a solid, long‑term growth story in Medicaid and Medicare Advantage.

Centene’s new community‑investment plan could cut Medicaid costs by up to $15 m annually while boosting quality metrics, positioning the company for stronger value‑based contracts and higher investor confidence.